Trending...
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- KeysCaribbean Offers 20 Percent Off Seven-Night Stays For Private Home Collection Properties
- dpInk Ltd. Liability Company Ignites Strategic Growth for Small Businesses and Visionary Enterprises
CHAPPAQUA, N.Y. - Marylandian -- Metadichol®, a nano lipid formulation of long chain alcohols, has been shown in vitro studies to be an anti-viral for SARS-COV-2 (the COVID-19 virus) and it does so by blocking the cell entry points for SARS-COV-2. The receptor ACE2 is used by the virus for entry and the serine protease TMPRSS2 for S protein priming. It inhibits both ACE2 and TMPRSS2. An anti-viral assay against the virus using CACO2 cells showed that it had an EC90 of 0.16 µg/ml, which means it effectively eliminates the virus at a very low concentration.
Metadichol® inhibits TMPRSS2 (EC50 of 96 ng/ml). It is 270 times more potent than another another well known inhibitor Camostat mesylate, which has EC50 of (26000 ng/ml). Metadichol is also a moderate inhibitor of ACE2 with an EC50 of 31 µg/ml. Moderate inhibition of ACE2 allows it to perform its key functions in the body, yet fend off SARS-COV-2 entry to the cell. ACE2 lowers blood pressure, regulates intestinal neutral amino acid transport. ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.
More on Marylandian
Metadichol, by binding to the Vitamin D receptor (VDR), acts on proteases like Furin and Adam-17, which activate the S-protein spikes for viral spread and pathogenesis in the infected hosts. In Malaria, CD147, also known as Basigin, is used by parasites to gain entry into the cell. Recent publications suggest that it also can be used as a point of entry by the SARS-COV-2 virus. Our previous work (US patent 9,006,292) showed that Metadichol is also potent against Malarial parasites and, by association, CD147. All these results and others are documented in our recent publication available at (https://www.researchsquare.com/article/rs-34021/v1)
A pilot study (outside the USA) on five COVID-19 patients with minor symptoms showed the absence of a virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have initiated a study in collaboration with government agencies. The initial study of 30 patients showed 75% of the patients cleared of the SARS-COV-2 virus after 4 days of treatment - see http://nanorxeurope.com/Documents/India-hospital-letter.pdf.
More on Marylandian
Metadichol is a safe, non-toxic product made from renewable sources and commercially available with no reported side effects. This unique property allows for the use of Metadichol in a situation that exists today and also to prevent future occurrence of SARS-COV-2 and other infections, and use of it worldwide would allow normal human activity everywhere.
Patent details and publications can be found at https://www.researchgate.net/profile/Palayakotai_Raghavan.
Metadichol, marketed as Nano Soma can be found at www.thenanosoma.com and http://www.nanosoma.net, whilst Nano-Ojas can be found at www.nanoojas.net and Metadichol at www.gen100.com.
Metadichol is available as an oral or topical spray, a topical (or oral) gel and a face cream.
For further information contact:
media_relations@nanorxeurope.com
+1 443 769 1752 (USA)
+44 1212 840 929 (UK)
+61 3 9021 6920 (AUSTRALIA)
+31 30 808 045 (HOLLAND)
+91 98194 85080 (INDIA)
Metadichol® inhibits TMPRSS2 (EC50 of 96 ng/ml). It is 270 times more potent than another another well known inhibitor Camostat mesylate, which has EC50 of (26000 ng/ml). Metadichol is also a moderate inhibitor of ACE2 with an EC50 of 31 µg/ml. Moderate inhibition of ACE2 allows it to perform its key functions in the body, yet fend off SARS-COV-2 entry to the cell. ACE2 lowers blood pressure, regulates intestinal neutral amino acid transport. ACE2 expression and function is increasingly recognized as a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.
More on Marylandian
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
- Easton & Easton, LLP Sues The Dwelling Place Anaheim and Vineyard USA for Failing to Protect Minor from Church Leaders' Sexual Abuse
Metadichol, by binding to the Vitamin D receptor (VDR), acts on proteases like Furin and Adam-17, which activate the S-protein spikes for viral spread and pathogenesis in the infected hosts. In Malaria, CD147, also known as Basigin, is used by parasites to gain entry into the cell. Recent publications suggest that it also can be used as a point of entry by the SARS-COV-2 virus. Our previous work (US patent 9,006,292) showed that Metadichol is also potent against Malarial parasites and, by association, CD147. All these results and others are documented in our recent publication available at (https://www.researchsquare.com/article/rs-34021/v1)
A pilot study (outside the USA) on five COVID-19 patients with minor symptoms showed the absence of a virus after 2-4 days of Metadichol @ 20 mg per day. To validate this further, we have initiated a study in collaboration with government agencies. The initial study of 30 patients showed 75% of the patients cleared of the SARS-COV-2 virus after 4 days of treatment - see http://nanorxeurope.com/Documents/India-hospital-letter.pdf.
More on Marylandian
- Lokal Media House Earns ServiceTitan Certified Marketer Status
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
- Poised for Major Growth with Strategic Military Orders, Global Expansion, and Groundbreaking Underground Mining Initiative $RMXI
- XRP fever is coming again, WOA Crypto helps the new trend and earns tens of thousands of dollars a day
- Helen Welch Stars in "Carpenters: The Songs. The Stories" at New Spire Arts
Metadichol is a safe, non-toxic product made from renewable sources and commercially available with no reported side effects. This unique property allows for the use of Metadichol in a situation that exists today and also to prevent future occurrence of SARS-COV-2 and other infections, and use of it worldwide would allow normal human activity everywhere.
Patent details and publications can be found at https://www.researchgate.net/profile/Palayakotai_Raghavan.
Metadichol, marketed as Nano Soma can be found at www.thenanosoma.com and http://www.nanosoma.net, whilst Nano-Ojas can be found at www.nanoojas.net and Metadichol at www.gen100.com.
Metadichol is available as an oral or topical spray, a topical (or oral) gel and a face cream.
For further information contact:
media_relations@nanorxeurope.com
+1 443 769 1752 (USA)
+44 1212 840 929 (UK)
+61 3 9021 6920 (AUSTRALIA)
+31 30 808 045 (HOLLAND)
+91 98194 85080 (INDIA)
Source: NanoRX Inc.
0 Comments
Latest on Marylandian
- The World Needs You—The Elevated Leader
- Keebos Launches Crossbody Cases for Every iPhone 17 Model
- WOA Crypto redefines cloud Bitcoin mining, offering free access and instant profit opportunities
- Pepperdine University Malibu, California and Community Partners Recognized with 2025 ReadyCommunities Partnership National Service Award
- NBA Overachievers: OddsTrader Reveals Which Teams Will Exceed Expectations in 2025-26
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
- The OpenSSL Corporation and the OpenSSL Foundation Celebrate the Success of the Inaugural OpenSSL Conference in Prague
- TKL Group's New Factory Commences Production, Pioneering A New Era In Global Heavy Duty Truck Parts
- Regulated Crypto Exchange TZNXG Addresses Core US Market Challenges with Compliance-First Infrastructure
- GitKraken Launches Insights to Help Engineering Leaders Quantify AI Impact and Improve Developer Experience
- ZapperBox NextGen TV Gateway Receiver Now Testing Support For Secure Whole-Home Content Distribution
- Life as a Dog: P-Wave Press Brings Readers a Heartwarming Memoir of Love, Laughter and Companionship
- NOYA Launches Premium, Design-Forward Training Gear That Belongs at the Center of Your Space
- Research Defense Examines Violence, Illiteracy, Non-Active Fathers, and Low Self-Esteem Among Males
- Investing in Greece: Your Definitive Real-Estate FAQ Guide
- KeysCaribbean Offers 20 Percent Off Seven-Night Stays For Private Home Collection Properties
- Advancing Circular Economy in Automotive ESD Packaging
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"
- CCHR Exposes Conflicted Psychiatrists Behind Teen Antidepressant Surge